Compare this medication with others →
Adalimumab-Adbm
CY2024| share of claims | prescribers, this brand row | |
|---|---|---|
| Cyltezo(Cf) Pen | 82.0% | 966 |
| Cyltezo(Cf) | 9.2% | 149 |
| Adalimumab-Adbm(Cf)pen | 5.2% | 118 |
| Adalimumab-Adbm(Cf) | 1.5% | 50 |
- Market size 8,014 claims for Adalimumab-Adbm in CY2024, and 8,308 30-day fills, as CMS publishes them.
- Prescribers CMS reports prescribers for each of the 7 brand rows, on the Brands and generics tab. Counts are per brand and are never summed.
- Where it is prescribed The three largest state markets are Florida, Massachusetts, and Texas — together 21.5% of claims.
Claims count dispensed fills, refills included; a claim is not a prescription written and not a patient count. CMS withholds any prescriber with 10 or fewer claims for a brand row, so a prescriber missing from a list is not confirmed absent and every disclosed count is a floor. Totals and prescriber rows come from two separate CMS files that are not built to reconcile, so a prescriber list never adds up to a published total. Shares are computed only against the totals CMS publishes for the place. Prescriber counts belong to one brand row and are never summed across brands, because one clinician can write several brands. All figures are calendar years.
This medication's Overview — its five-year claims trend, and how many state markets publish a total for it — is part of Explore.
Where this medication is prescribed, state by state, is part of a Deep Dive.
The clinicians who prescribe this medication, ranked by claims, are part of a Deep Dive.
This medication's brands and generics, with their claims and fills, are part of a Deep Dive.
See the Part D drug cost
An Explore subscription, $249 a seat a year, opens this medication's Overview, and shows what Medicare Part D spends on it.
It comes with 25 credits a seat a year for Deep Dives, which open the rest.
Included in Explore. Part of a Deep Dive.